With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...
Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies. For example, Nvidia owns stakes in ...
Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Indeed, Nvidia tends to play the long game with its ...
That brings us to Recursion Pharmaceuticals (RXRX +3.86%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results